Effect of the CYP3A inhibitor ketoconazole on the pharmacokinetics and pharmacodynamics of bortezomib in patients with advanced solid tumors: A prospective, multicenter, open-label, randomized, two-way crossover drug-drug interaction study

Clinical Therapeutics

Volumn 31, Issue PART. 2, 2009, Pages 2444-2458

  Venkatakrishnan, Karthik ^a   Rader, Michael ^b   Ramanathan, Ramesh K ^c   Ramalingam, Suresh ^c   Chen, Eric ^d   Riordan, William ^a   Trepicchio, William ^a   Cooper, Michael ^e   Karol, Michael ^f   von Moltke, Lisa ^a   Neuwirth, Rachel ^a   Egorin, Merrill ^c   Chatta, Gurkamal ^c  

^a MILLENNIUM PHARMACEUTICALS INC   (United States)

^b Nyack Hospital   (United States)

^c UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

^d PRINCESS MARGARET HOSPITAL   (Canada)

^e NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH   (United States)

^f Synta Pharmaceuticals Corp   (United States)

Author keywords

bortezomib; drug drug; interaction; ketoconazole; pharmacodynamics; pharmacokinetics; solid tumors

Indexed keywords

BORTEZOMIB; CYTOCHROME P450 3A; KETOCONAZOLE; PROTEASOME;

ADENOCARCINOMA; ADULT; ADVANCED CANCER; AGED; ANEMIA; AREA UNDER THE CURVE; ARTICLE; BEDTIME DOSAGE; BLOOD SAMPLING; BONE METASTASIS; CANCER COMBINATION CHEMOTHERAPY; CLINICAL ARTICLE; CLINICAL TRIAL; COLON CANCER; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DOSE REDUCTION; DRUG EFFECT; DRUG EFFICACY; DRUG EXPOSURE; DRUG FATALITY; DRUG MECHANISM; DRUG POTENTIATION; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPNEA; ENZYME INHIBITION; FATIGUE; FEMALE; HUMAN; INSOMNIA; LIVER METASTASIS; LUNG CANCER; LUNG METASTASIS; LYMPH NODE METASTASIS; MALE; MONOTHERAPY; MORNING DOSAGE; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUROTOXICITY; PROSTATE CANCER; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SOLID TUMOR; THROMBOCYTOPENIA; VOMITING; WEIGHT REDUCTION;

ANTIFUNGAL AGENTS; ANTINEOPLASTIC AGENTS; AREA UNDER CURVE; BORONIC ACIDS; CROSS-OVER STUDIES; CYTOCHROME P-450 CYP3A; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; DRUG INTERACTIONS; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; KETOCONAZOLE; MALE; MIDDLE AGED; NEOPLASMS; PROSPECTIVE STUDIES; PYRAZINES;

EID: 74549173179     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2009.11.012     Document Type: Article

References (51)

1. Kane R.C., Farrell A.T., Sridhara R., and Pazdur R. United States Food and Drug Administration approval summary: Bortezomib for the treatment of progressive multiple myeloma after one prior therapy. Clin Cancer Res. 12 (2006) 2955-2960
2. Kane R.C., Dagher R., Farrell A., et al. Bortezomib for the treatment of mantle cell lymphoma. Clin Cancer Res. 13 (2007) 5291-5294
3. VELCADE (bortezomib) for injection [prescribing information] (2008), Millennium Pharmaceuticals Inc, Cambridge, Mass
4. San Miguel J.F., Schlag R., Khuageva N.K., et al., VISTA Trial Investigators. Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma. N Engl J Med. 359 (2008) 906-917
5. Rajkumar S.V., Richardson P.G., Hideshima T., and Anderson K.C. Proteasome inhibition as a novel therapeutic target in human cancer. J Clin Oncol. 23 (2005) 630-639
6. Voorhees P.M., Dees E.C., O'Neil B., and Orlowski R.Z. The proteasome as a target for cancer therapy. Clin Cancer Res. 9 (2003) 6316-6325
7. Ling Y.H., Liebes L., Ng B., et al. PS-341, a novel proteasome inhibitor, induces Bcl-2 phosphorylation and cleavage in association with G2-M phase arrest and apoptosis. Mol Cancer Ther. 1 (2002) 841-849
8. Adams J., Palombella V.J., Sausville E.A., et al. Proteasome inhibitors: A novel class of potent and effective antitumor agents. Cancer Res. 59 (1999) 2615-2622
9. Shah S.A., Potter M.W., McDade T.P., et al. 26S Proteasome inhibition induces apoptosis and limits growth of human pancreatic cancer. J Cell Biochem. 82 (2001) 110-122
10. Russo S.M., Tepper J.E., Baldwin Jr. A.S., et al. Enhancement of radiosensitivity by proteasome inhibition: Implications for a role of NF-kappaB. Int J Radiat Oncol Biol Phys. 50 (2001) 183-193
11. Jagannath S., Barlogie B., Berenson J., et al. A phase 2 study of two doses of bortezomib in relapsed or refractory myeloma. Br J Haematol. 127 (2004) 165-172
12. Richardson P.G., Barlogie B., Berenson J., et al. A phase 2 study of bortezomib in relapsed, refractory myeloma. N Engl J Med. 348 (2003) 2609-2617
13. Fisher R.I., Bernstein S.H., Kahl B.S., et al. Multicenter phase II study of bortezomib in patients with relapsed or refractory mantle cell lymphoma. J Clin Oncol. 24 (2006) 4867-4874
14. Richardson P.G., Sonneveld P., Schuster M.W., et al., Assessment of Proteasome Inhibition for Extending Remissions (APEX) Investigators. Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. N Engl J Med. 352 (2005) 2487-2498
15. San Miguel J.F., Schlag R., Khuageva N., et al. MMY-3002: A phase 3 study comparing bortezomib-melphalan-prednisone (VMP) with melphalan-prednisone (MP) in newly diagnosed multiple myeloma. ASH Annual Meeting Abstracts. Blood. 110 (2007) 76
16. Harousseau J.L., Mathiot C., Attal M., et al. VELCADE/ dexamethasone (Vel/D) versus VAD as induction treatment prior to autologous stem cell transplantation (ASCT) in newly diagnosed multiple myeloma (MM): Updated results of the IFM 2005/01 trial. Blood. ASH Annual Meeting Abstracts. Blood. 110 (2007) 450
17. Cavo M., Patriarca F., Tacchetti P., et al. Bortezomib (Velcade)-thalidomide-dexamethasone (VTD) vs thalidomide-dexamethasone (TD) in preparation for autologous stem- cell (SC) transplantation (ASCT) in newly diagnosed multiple myeloma (MM). ASH Annual Meeting Abstracts. Blood. 110 (2007) 73
18. Aghajanian C., Soignet S., Dizon D.S., et al. A phase I trial of the novel proteasome inhibitor PS341 in advanced solid tumor malignancies. Clin Cancer Res. 8 (2002) 2505-2511
19. Papandreou C.N., Daliani D.D., Nix D., et al. Phase I trial of the proteasome inhibitor bortezomib in patients with advanced solid tumors with observations in androgenindependent prostate cancer. J Clin Oncol. 22 (2004) 2108-2121
20. Aghajanian C., Dizon D.S., Sabbatini P., et al. Phase I trial of bortezomib and carboplatin in recurrent ovarian or primary peritoneal cancer. J Clin Oncol. 23 (2005) 5943-5949
21. Messersmith W.A., Baker S.D., Lassiter L., et al. Phase I trial of bortezomib in combination with docetaxel in patients with advanced solid tumors. Clin Cancer Res. 12 (2006) 1270-1275
22. Ryan D.P., O'Neil B.H., Supko J.G., et al. A Phase I study of bortezomib plus irinotecan in patients with advanced solid tumors. Cancer. 107 (2006) 2688-2697
23. Ryan D.P., Appleman L.J., Lynch T., et al. Phase I clinical trial of bortezomib in combination with gemcitabine in patients with advanced solid tumors. Cancer. 107 (2006) 2482-2489
24. Voortman J., Smit E.F., Honeywell R., et al. A parallel dose-escalation study ofweekly and twice-weekly bortezomib in combination with gemcitabine and cisplatin in the firstline treatment of patients with advanced solid tumors. Clin Cancer Res. 13 (2007) 3642-3651
25. Pekol T., Daniels J.S., Labutti J., et al. Human metabolism of the proteasome inhibitor bortezomib: Identification of circu- lating metabolites. Drug Metab Dispos. 33 (2005) 771-777
26. Uttamsingh V., Lu C., Miwa G., and Gan L.S. Relative contributions of the five major human cytochromes P450, 1A2, 2C9, 2C19, 2D6, and 3A4, to the hepatic metabolism of the proteasome inhibitor bortezomib. Drug Metab Dispos. 33 (2005) 1723-1728
27. Blower P., de Wit R., Goodin S., and Aapro M. Drug-drug interactions in oncology: Why are they important and can they be minimized?. Crit Rev Oncol Hematol. 55 (2005) 117-142
28. NIZORAL. (ketoconazole) [prescribing information] (2001), Janssen Pharmaceutica Products LP, Titusville, NJ
29. Bjornsson T.D., Callaghan J.T., Einolf H.J., et al., Pharmaceutical Research and Manufacturers of America Drug Metabolism/Clinical Pharmacology Technical Working Groups. The conduct of in vitro and in vivo drug-drug interaction studies: A PhRMA perspective. J Clin Pharmacol. 43 (2003) 443-469
30. Venkatakrishnan K., von Moltke L.L., and Greenblatt D.J. Effects of antifungal agents on oxidative drug metabo- lism: Clinical relevance. Clin Pharma- cokinet. 38 (2000) 111-180
31. US Food and Drug Administration, and Center for Drug Evaluation and Research. Draft Guidance for Industry: Drug Interaction Studies-Study Design, Data Analysis, and Implications for Dosing and Labeling. http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm072101.pdf Accessed September 15, 2009
32. Greenblatt D.J., Wright C.E., von Moltke L.L., et al. Ketoconazole inhibition of triazolam and alprazolam clearance: Differential kinetic and dynamic consequences. Clin Pharmacol Ther. 64 (1998) 237-247
33. Kehrer D.F., Mathijssen R.H., Verweij J., et al. Modulation of irinotecan metabolism by ketoconazole. J Clin Oncol. 20 (2002) 3122-3129
34. von Moltke L.L., Greenblatt D.J., Harmatz J.S., et al. Triazolam biotrans- formation by human liver microsomes in vitro: Effects of metabolic inhibitors and clinical confirmation of a predicted interaction with ketoconazole. J Pharmacol Exp Ther. 276 (1996) 370-379
35. Dutreix C., Peng B., Mehring G., et al. Pharmacokinetic interaction between ketoconazole and imatinib mesylate (Glivec) in healthy subjects. Cancer Chemother Pharmacol. 54 (2004) 290-294
36. Rakhit A., Pantze M.P., Fettner S., et al. The effects of CYP3A4 inhibition on erlotinib pharmacokinetics: Computer-based simulation (Sim-CYP) predicts in vivo metabolic in- hibition. Eur J Clin Pharmacol. 64 (2008) 31-41
37. The World Medical Association (WMA). World Medical Association Declaration of Helsinki: Ethical principles for medical research involving human subjects. http://www.wma.net/e/policy/b3.htm Accessed August 19, 2009
38. Karnofsky D.A., and Burchenal J.H. The clinical evaluation of chemotherapeutic agents in cancer. In: Macleod C.M. (Ed). Evaluation of Chemotherapeutic Agents (1949), Columbia University Press, New York, NY 199-205
39. National Cancer Institute Cancer Therapy Evaluation Program Com- mon Terminology Criteria for Adverse Events, Version 3.0 (2006). http://ctep.cancer.gov/forms/CTCAEv3.pdf Accessed August 19, 2009
40. Rowland M., and Tozer T.N. Clinical Pharmacokinetics: Concepts and Applications. 3rd ed. (1995), Williams & Wilkins, Baltimore, Md
41. Lightcap E.S., McCormack T.A., Pien C.S., et al. Proteasome inhibition measurements: Clinical application. Clin Chem. 46 (2000) 673-683
42. Calhoun E.A., Welshman E.E., Chang C.H., et al. Psychometric evaluation of the Functional Assessment of Cancer Therapy/Gynecologic Oncology Group-Neurotoxicity (Fact/ GOG-Ntx) questionnaire for patients receiving systemic chemo- therapy. Int J Gynecol Cancer. 13 (2003) 741-748
43. Jones B., and Kenward M.G. Design and Analysis of Cross-Over Trials. 2nd ed. (2003), Chapman & Hall/ CRC, Boca Raton, Fla
44. Stewart K.A., Sullivan D., Lonial S., et al. Pharmacokinetic (PK) and pharmacodynamics (PD) study of two doses of bortezomib (Btz) in patients with relapsed multiple myeloma. ASH Annual Meeting Abstracts. Blood. 108 (2006) 3533
45. Saari T.I., Laine K., Leino K., et al. Effect of voriconazole on the pharmacokinetics and pharmacodynamics of intravenous and oral midazolam. Clin Pharmacol Ther. 79 (2006) 362-370
46. Majumdar A.K., McCrea J.B., Panebianco D.L., et al. Effects of aprepitant on cytochrome P450 3A4 activity using midazolam as a probe. Clin Pharmacol Ther. 74 (2003) 150-156
47. Gorski J.C., Jones D.R., Haehner-Daniels B.D., et al. The contribution of intestinal and hepatic CYP3A to the interaction between midazolam and clarithromycin. Clin Pharmacol Ther. 64 (1998) 133-143
48. Coleman M., Leonard J., Lyons L., et al. BLT-D (clarithromycin [Biaxin], low-dose thalidomide, and dexamethasone) for the treatment of myeloma and Waldenstrom's macroglobulinemia. Leuk Lymphoma. 43 (2002) 1777-1782
49. Niesvizky R., Jayabalan D.S., Christos P.J., et al. BiRD (Biaxin [clarithromycin]/Revlimid [lenaldomide]/dexamethasone) combination therapy results in high complete- and overallresponse rates in treatment-naive symptomatic multiple myeloma. Blood. 111 (2008) 1101-1109
50. Cheung M.C., Pantanowitz L., and Dezube B.J. AIDS-related malignancies: Emerging challenges in the era of highly active antiretroviral therapy. Oncologist. 10 (2005) 412-426
51. Quinn D.I., Nemunaitis J., Fuloria J., et al. Effect of the cytochrome P450 2C19 inhibitor omeprazole on the pharmacokinetics and safety profile of bortezomib in patients with advanced solid tumours, non-Hodgkin's lymphoma or multiple myeloma. Clin Pharmacokinet. 48 (2009) 199-209